HC Wainwright & Co. Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $60

Benzinga Newsdesk www.benzinga.com Neutral 49.9%

Neg 0% Neu 49.9% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $60.